8:30 am |
Welcome, overview, and committee introductions Claire V. Broome, IOM Committee Chair
|
8:45 am |
Panel 1– Development of new vaccines and those needed for global use |
|
Moderator: Claire Broome, IOM committee chair Topics of discussion may include: - Setting priorities
- Scientific challenges
- Regulatory issues
- Implementation issues
- Advocacy/policy communication issues
- Role of non-Western vaccine companies as vaccine developers and suppliers for both developed and developing nations
Discussants Norman Baylor, CBER/FDA (by phone)
Brent Burkholder, NCIRD/CDC
Thomas Cherian, WHO
Margaret McCluskey, USAID
Mark Feinberg, Merck
John Ferguson, Novartis Vaccines & Diagnostics
Orin Levine, Johns Hopkins University
Adel Mahmoud, Princeton University (by phone)
Regina Rabinovich, Gates Foundation
Jerald Sadoff, Aeras Global TB Vaccine Foundation
Theodore Tsai, Novartis
Justin Wright, BD Medical-Pharmaceutical Systems
|
10:30 am |
Break |
|
|
10:45 am |
Panel 2 – Immunization program issues: infra-structure, communication, impact of eradication/elimination Moderator: Milagritos Tapia, IOM committee member Topics of discussion may include: - Quality and safety of administration, storage, inventory management, cold chain, other infrastructure issues
- Impact of health systems "reform”,
- Are vaccines reaching those at highest risk of disease?
- Innovative approaches to target high-risk/hard-to-reach groups
- Implications of target populations with high proportion of HIV infected
Discussants Brent Burkholder, NCIRD/CDC
Thomas Cherian, WHO
Rod Hausser, BD Medical-Pharmaceutical Systems
Orin Levine, Johns Hopkins University
Margaret McCluskey, USAID
Robert Steinglass, John Snow Inc.
Linda Venczel, Gates Foundation |
|
|
12:30 pm |
Lunch |
|
|
1:30 pm |
Panel 3 – Surveillance of safety, effectiveness, coverage, disease Moderator: Art Reingold, IOM committee member Topics of discussion may include: - Immunization program monitoring and evaluation
- Coverage measurement vs disease impact
- Challenges of safety monitoring eg Yellow Fever vaccine in Africa
Discussants Brent Burkholder, NCIRD/CDC
John Ferguson, Novartis Vaccines & Diagnostics
David Fleming, Director & Health Officer, WA
Kathy Neuzil, PATH
Robert Steinglass, John Snow Inc.
Linda Venczel, Gates Foundation |
|
|
3:15 pm |
Break |
|
|
3:30 pm |
Panel 4 – Financing vaccine development and purchase Moderator: David Paltiel, IOM committee member Topics of discussion may include: - Financing new vaccine development
- financing purchase of expensive new vaccines (eg pneumococcal conjugate, HPV)
- sustainable support for new vaccines by developing countries
- experience with novel financing approaches—IIFM, AMC, Gates (pros and cons)
- Prioritizing support for optimal use of existing vaccines vs development of new vaccines
Discussants Brent Burkholder, NCIRD/CDC
Orin Levine, Johns Hopkins University
Melinda Moree, Global Health Services
Regina Rabinovich, Gates Foundation
Jerald Sadoff, Aeras Global TB Vaccine Foundation |
|
|
5:30 pm |
Adjourn |